Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
  • NCT04308681
The Idiopathic Pulmonary Fibrosis (IPF) cohort in this protocol is now closed. The study is only enrolling patients onto the Progressive Fibrotic Interstitial Lung Disease (PF-ILD) cohort.

Active, Not Recruiting

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis - IM027-040

Updated: 26 July, 2023   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page IM027-040
Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

  • Phase 2

    Phase

  • Gender(s)

  • 21+

    Age Range

  • Active, Not Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: IPF Dose 1 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Experimental: IPF Dose 2 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Placebo Comparator: IPF Placebo + Post Treatment Follow-up or OTE
Other: BMS-986278 Placebo
Experimental: PF-ILD Dose 1 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Experimental: PF-ILD Dose 2 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Placebo Comparator: PF-ILD Placebo + Post Treatment Follow-up or OTE
Other: BMS-986278 Placebo

Key Eligibility Criteria

Inclusion Criteria: For the idiopathic pulmonary fibrosis (IPF) Cohort - Diagnosis of IPF within 7 years of screening - Female and males ≥ 40 years of age For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort - Evidence of progressive ILD within the 24 months before screening - Female and male ≥ 21 years of age. Exclusion Criteria: - Women of childbearing potential (WOCBP) - Active Smokers - Current malignancy or previous malignancy up to 5 years prior to screening - History of allergy to BMS-986278 or related compounds Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com